Robert Conway Biography and Net Worth

Chairman of ARCA biopharma


Mr. Conway, age 65, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. Mr. Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded pharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of eResearch Technology, Inc., a private company, and from 2015 to July 2017, he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July 2017, Nivalis Therapeutics, Inc. combined with Alpine Immune Sciences, Inc., a public, clinical stage pharmaceutical company, and Mr. Conway continues to serve on the board of directors following such combination. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Signant Health and Adverra, Inc. Mr. Conway received a B.S. in accounting from Marquette University in 1976.

What is Robert E. Conway's net worth?

The estimated net worth of Robert E. Conway is at least $0.00 as of May 12th, 2021. Mr. Conway owns 347 shares of ARCA biopharma stock worth more than $0 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Conway may own. Learn More about Robert E. Conway's net worth.

How do I contact Robert E. Conway?

The corporate mailing address for Mr. Conway and other ARCA biopharma executives is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. ARCA biopharma can also be reached via phone at (720) 940-2100 and via email at [email protected]. Learn More on Robert E. Conway's contact information.

Has Robert E. Conway been buying or selling shares of ARCA biopharma?

Robert E. Conway has not been actively trading shares of ARCA biopharma within the last three months. Most recently, on Wednesday, May 12th, Robert E. Conway bought 69 shares of ARCA biopharma stock. The stock was acquired at an average cost of $459.36 per share, with a total value of $31,695.84. Following the completion of the transaction, the chairman now directly owns 347 shares of the company's stock, valued at $159,397.92. Learn More on Robert E. Conway's trading history.

Who are ARCA biopharma's active insiders?

ARCA biopharma's insider roster includes Robert Conway (Chairman), and Christopher Ozeroff (VP). Learn More on ARCA biopharma's active insiders.

Are insiders buying or selling shares of ARCA biopharma?

During the last year, ARCA biopharma insiders bought shares 6 times. They purchased a total of 3,421 shares worth more than $1,666,176.48. The most recent insider tranaction occured on August, 16th when Major Shareholder Henderson Group Plc Janus bought 40 shares worth more than $16,876.80. Insiders at ARCA biopharma own 30.9% of the company. Learn More about insider trades at ARCA biopharma.

Information on this page was last updated on 8/16/2024.

Robert E. Conway Insider Trading History at ARCA biopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2021Buy69$459.36$31,695.84347View SEC Filing Icon  
5/5/2021Buy69$465.12$32,093.28277View SEC Filing Icon  
12/18/2020Buy69$599.04$41,333.76208View SEC Filing Icon  
9/25/2020Buy34$616.32$20,954.88138View SEC Filing Icon  
9/21/2020Buy69$686.88$47,394.7282View SEC Filing Icon  
7/14/2017Buy69$358.56$24,740.64243View SEC Filing Icon  
3/24/2017Buy173$372.96$64,522.08173View SEC Filing Icon  
See Full Table

Robert E. Conway Buying and Selling Activity at ARCA biopharma

This chart shows Robert E Conway's buying and selling at ARCA biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ARCA biopharma Company Overview

ARCA biopharma logo
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $384.99
Low: $2.40
High: $599.04

2 Week Range

Now: N/A

Volume

290,800 shs

Average Volume

607,995 shs

Market Capitalization

$34.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91